Objective:To investigate the clinical efficacy of applying the combination of montelukast sodium and xinpocetine in the treatment of asthmatic patients,to provide clinical reference.Methods:110 cases of asthma patients admitted to the hospital from July 2020 to July 2021 were selected as the study subjects and were divided into the control group and observation group according to the random number table method,with 55 cases in each group.The control group was treated with Sinebicol,and the observation group was treated with montelukast sodium on this basis,and both groups continued to be treated for 4 weeks.The treatment effect,inflammatory factor level,changes in lung function indexes and adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group(92.73%)was higher than that in the control group(70.91%),and the difference was statistically significant(x2=8.80,P＜0.05).After treatment,the time to relieve symptoms of cough,wheezing,and lung rales was lower in the observation group than in the control group,and the difference was statistically significant(t=12.236,5.927,14.396,P＜0.05).C-reactive protein(CRP)and interleukin-6(IL-6)were lower in the observation group than in the control group,and the difference was statistically significant(t=12.126,11.108,P＜0.05).After treatment,peak expiratory flow rate(PEFR),forceful lung capacity(FVC),and forceful expiratory volume in the 1st s(FEV1)of the observation group were higher than those of the control group,and the differences were statistically significant(t=11.314,2.247,3.066,P＜0.05).Conclusion:The combination of montelukast sodium and xinbicol can reduce the inflammatory response of asthma patients,improve their lung function,enhance clinical efficacy,and can be used as a safe and effective treatment modality.
维普
万方数据